MIF and acute kidney injury: We further explored whether the mRNA and protein levels of MIF were concurrently elevated by IGF2BP1 in septic AKI, and examined the half-life of the remaining MIF mRNA in cells treated with actinomycin D (Act D), which is a pan-RNA synthesis inhibitor 45.